Giapreza Clinical Development Timeline
Chronicle of the development and US FDA review of La Jolla Pharmaceutical's angiotensin II for increasing blood pressure in adults with septic or other distributive shock.
You may also be interested in...
FDA is worried about drug names that could appear to overstate efficacy and impact consumer and healthcare provider perceptions of the product.
Enasidenib, which last year became the first US-approved treatment for relapsed or refractory acute myeloid leukemia with an IDH2 mutation, is among a new crop of products being reviewed for marketing approval in the EU.
Chronicle of the development and US FDA review of Advanced Accelerator Applications' lutetium Lu 177 dotatate for gastroenteropancreatic neuroendocrine tumors.